AU2002225219A1 - Diagnosis and treatment of multiple sclerosis - Google Patents
Diagnosis and treatment of multiple sclerosisInfo
- Publication number
- AU2002225219A1 AU2002225219A1 AU2002225219A AU2002225219A AU2002225219A1 AU 2002225219 A1 AU2002225219 A1 AU 2002225219A1 AU 2002225219 A AU2002225219 A AU 2002225219A AU 2002225219 A AU2002225219 A AU 2002225219A AU 2002225219 A1 AU2002225219 A1 AU 2002225219A1
- Authority
- AU
- Australia
- Prior art keywords
- diagnosis
- treatment
- multiple sclerosis
- sclerosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/285—Demyelinating diseases; Multipel sclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26440401P | 2001-01-26 | 2001-01-26 | |
US60/264,404 | 2001-01-26 | ||
US33164701P | 2001-11-20 | 2001-11-20 | |
US60/331,647 | 2001-11-20 | ||
PCT/GB2002/000330 WO2002059604A2 (en) | 2001-01-26 | 2002-01-25 | Diagnosis and treatment of multiple sclerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002225219A1 true AU2002225219A1 (en) | 2002-08-06 |
Family
ID=26950517
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002225219A Abandoned AU2002225219A1 (en) | 2001-01-26 | 2002-01-25 | Diagnosis and treatment of multiple sclerosis |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1354199A2 (ja) |
JP (1) | JP2004532386A (ja) |
AU (1) | AU2002225219A1 (ja) |
WO (1) | WO2002059604A2 (ja) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5048201B2 (ja) | 2000-08-04 | 2012-10-17 | ディーエムアイ バイオサイエンシズ インコーポレイテッド | ジケトピペラジン類の使用方法とジケトピペラジン類を含む組成物 |
US7015004B2 (en) * | 2001-11-23 | 2006-03-21 | Syn X Pharma, Inc. | Inter-alpha trypsin inhibitor biopolymer marker indicative of insulin resistance |
US20030113808A1 (en) * | 2001-12-13 | 2003-06-19 | George Jackowski | Apolipoprotein biopolymer markers predictive of alzheimers disease |
AU2004222345A1 (en) * | 2003-03-14 | 2004-09-30 | Ppd Biomarker Discovery Sciences, Llc | Biological markers for diagnosing rheumatoid arthritis |
ES2572975T3 (es) | 2003-05-15 | 2016-06-03 | Ampio Pharmaceuticals, Inc. | Tratamiento de enfermedades mediadas por los linfocitos T |
US9408891B2 (en) | 2003-11-12 | 2016-08-09 | The Trustees Of The University Of Pennsylvania | Methods of using gelsolin to treat or prevent bacterial sepsis |
WO2005112970A2 (en) | 2004-05-12 | 2005-12-01 | The Brigham And Women's Hospital, Inc. | Use of gelsolin to treat infections |
US20050266467A1 (en) * | 2004-05-19 | 2005-12-01 | Ppd Biomarker Discovery Sciences, Llc | Biomarkers for multiple sclerosis and methods of use thereof |
WO2006005583A2 (en) * | 2004-07-12 | 2006-01-19 | Geneprot Inc. | Secreted polypeptide species involved in multiple sclerosis |
WO2006069739A2 (en) * | 2004-12-27 | 2006-07-06 | Geneprot Inc. | Polypeptide species useful for the treatment of neurological disorders |
WO2006074787A2 (en) * | 2004-12-27 | 2006-07-20 | Geneprot Inc. | Polypeptide species useful for the treatment of neurological disorders |
US20070017809A1 (en) * | 2005-07-21 | 2007-01-25 | Power3 Medical Products, Inc. | Assay for ALS and ALS-like disorders |
JP5322917B2 (ja) | 2006-03-15 | 2013-10-23 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 炎症性疾患の診断および処置のためのゲルゾリンの使用 |
CN101460843B (zh) * | 2006-03-15 | 2018-06-22 | 布赖汉姆妇女医院有限公司 | 凝溶胶蛋白治疗多发性硬化和诊断神经疾病的用途 |
JPWO2009020058A1 (ja) * | 2007-08-03 | 2010-11-04 | 学校法人慶應義塾 | 脱髄病変へのドラッグデリバリーシステム及び脱髄病変の生化学的マーカー |
AU2013276992C1 (en) * | 2007-08-13 | 2016-08-11 | Takeda Pharmaceutical Company Limited | IVIG Modulations of Chemokines for Treatment of Multiple Sclerosis, Alzheimer's Disease, and Parkinson's Disease |
CA2695972A1 (en) | 2007-08-13 | 2009-02-19 | Baxter Healthcare S.A. | Ivig modulation of chemokines for treatment of multiple sclerosis, alzheimer's disease, and parkinson's disease |
WO2009094194A2 (en) | 2008-01-25 | 2009-07-30 | The General Hospital Corporation | Diagnostic and therapeutic uses of gelsolin in renal failure |
JP5856843B2 (ja) | 2008-05-27 | 2016-02-10 | アンピオ ファーマシューティカルズ,インコーポレイテッド | ジケトピペラジンを用いた医薬組成物 |
WO2010005387A1 (en) * | 2008-07-10 | 2010-01-14 | Astrazeneca Ab | New method and biomarkers for the diagnosis of multiple sclerosis |
EP2613786A4 (en) | 2010-09-07 | 2013-10-23 | Dmi Acquisition Corp | TREATMENT OF DISEASES |
US20140323324A1 (en) | 2010-12-16 | 2014-10-30 | National Institute Of Advanced Industrial Science And Technology | Method for Enrichment and Separation of Spinal Fluid Glycoprotein, Method for Searching for Marker for Central Nervous System Diseases Which Utilizes the Aforementioned Method, and Marker for Central Nervous System Diseases |
KR102032400B1 (ko) | 2011-10-10 | 2019-10-15 | 앰피오 파마슈티컬스 인코퍼레이티드 | 퇴행성 관절 질환의 치료 |
WO2013055749A1 (en) | 2011-10-10 | 2013-04-18 | Ampio Pharmaceuticals, Inc. | Implantable medical devices with increased immune tolerance, and methods for making and implanting |
SG10201605205VA (en) | 2011-10-28 | 2016-08-30 | Ampio Pharmaceuticals Inc | Treatment of rhinitis |
ITMI20120865A1 (it) * | 2012-05-18 | 2013-11-19 | Antonio Bertolotto | Biomarcatori per patologie del sistema nervoso centrale |
WO2014145729A2 (en) | 2013-03-15 | 2014-09-18 | Ampio Pharmaceuticals, Inc. | Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same |
RU2020136589A (ru) | 2014-08-18 | 2020-12-24 | Ампио Фармасьютикалз, Инк. | Лечение дегенеративных заболеваний суставов |
US11389512B2 (en) | 2015-06-22 | 2022-07-19 | Ampio Pharmaceuticals, Inc. | Use of low molecular weight fractions of human serum albumin in treating diseases |
RU2694614C1 (ru) * | 2019-01-22 | 2019-07-17 | Общество с ограниченной ответственностью "ВЕСТТРЭЙД ЛТД" (ООО "ВЕСТТРЭЙД ЛТД") | Способ определения активности патологического процесса у больных рассеянным склерозом |
WO2020172262A1 (en) * | 2019-02-19 | 2020-08-27 | James Janine | Chromium composition and methods thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2534999A (en) * | 1998-02-13 | 1999-08-30 | Oxford Glycosciences (Uk) Limited | Methods and compositions for diagnosis of hepatoma |
-
2002
- 2002-01-25 EP EP02715572A patent/EP1354199A2/en not_active Withdrawn
- 2002-01-25 WO PCT/GB2002/000330 patent/WO2002059604A2/en not_active Application Discontinuation
- 2002-01-25 JP JP2002559670A patent/JP2004532386A/ja active Pending
- 2002-01-25 AU AU2002225219A patent/AU2002225219A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2002059604A2 (en) | 2002-08-01 |
WO2002059604A8 (en) | 2002-11-21 |
WO2002059604A3 (en) | 2003-07-03 |
JP2004532386A (ja) | 2004-10-21 |
EP1354199A2 (en) | 2003-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002225219A1 (en) | Diagnosis and treatment of multiple sclerosis | |
AU2002323258A1 (en) | Diagnosis and treatment of vascular disease | |
AU2003290548A1 (en) | Prevention and treatment of synucleinopathic disease | |
AU2002247004A1 (en) | Methods of diagnosis and treatment of osteoporosis | |
AU2002367535A1 (en) | Diagnosis and treatment of vascular disease | |
AU2002314466A1 (en) | Withasol and methods of use | |
AU2002259130A1 (en) | Agents for treatment of hcv and methods of use | |
AU2002335085A1 (en) | Angiopoietins and methods of use thereof | |
AU2003268295A1 (en) | "diagnosis and treatment of infertility" | |
AU2002258728A1 (en) | Gene brcc-3 and diagnostic and therapeutic uses thereof | |
AU2002326813A1 (en) | Diagnosis and treatment of vascular disease | |
AU2002305151A1 (en) | Gene scc-112 and diagnostic and therapeutic uses thereof | |
AU2002303261A1 (en) | Gene brcc2 and diagnostic and therapeutic uses thereof | |
AU3760400A (en) | Methods and reagents for the diagnosis and treatment of multiple sclerosis | |
AU2002341880A1 (en) | Diagnosis and treatment of vascular disease | |
AU2002341604A1 (en) | Diagnosis and treatment of vascular disease | |
AU2002330724A1 (en) | Diagnosis, prevention and treatment of cancer | |
AU2003213898A1 (en) | Prevention and treatment of mycoplasma-associated diseases | |
EP1409734A4 (en) | DIAGNOSIS AND TREATMENT OF CANCER | |
GB2381272B (en) | Diagnosis and treatment of atherosclerosis | |
AU2002210286A1 (en) | Medicine intended for treatment of multiple sclerosis | |
AU2002249891A1 (en) | Compounds and methods for the diagnosis and treatment of babesia infection | |
AU2001267165A1 (en) | Prevention and treatment of mycoplasma-associated diseases | |
AU2002319591A1 (en) | Diagnosis and treatment of vascular disease | |
AU2002330649A1 (en) | Diagnosis and therapy of conditions involving alms1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |